Press Releases

2024

November
2024-11-19: Epiprotect Sales Expected to Triple in 2024 – with Continued Growth Targeted During the Year
2024-11-18: Clarification: S2Medical’s Transition to Semi-Annual Financial

October
2024-10-11: The last day for trading with BTAs has been changed to 16 October 2024 (SWE)
2024-10-07: S2Medical AB (publ) signs exclusive distribution agreement for Biopad in the Philippines (SWE)
2024-10-03: S2Medical AB (publ) receives patent approval in the USA for "Plantaricin NC8 Alpha Beta" – groundbreaking technology enhances antibiotic effectiveness (SWE)

September
2024-09-20: S2Medical AB (publ) Announces Final Outcome of the Company's Rights Issue (SWE)
2024-09-17: S2Medical AB (publ) Announces Preliminary Outcome of the Company's Rights Issue (SWE)
2024-09-16: S2Medical AB (publ) secures approval for attachment in Dubai – an important milestone for the recovery of 744,000.94 AED (SWE)
2024-09-13: S2Medical AB (publ) initiates commercialization of a cosmetic formulation based on skin health research and signs a letter of intent with Eyracure AB (SWE)
2024-09-03: The subscription period for the rights issue in S2Medical AB (publ) has begun, and the information memorandum is now published (SWE)

August
2024-08-28: S2Medical AB (publ) announces that the South African patent authorities have issued a patent for Eyracure's revolutionary molecule, BioLAP-20 (SWE)
2024-08-23: S2Medical AB (publ) carries out offensive rights issue of shares for approximately SEK 11.5 million (SWE)
2024-08-23: Interim report April - June 2024 (SWE)
2024-08-13: Acquisition of shares in Eyracure AB (SWE)

June
2024-06-20: Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study
2024-06-07: Announcement from the Annual General Meeting 2024 (SWE)

May
2024-05-30: S2Medical AB (publ) is now debt-free (SWE)
2024-05-17: Interim report January - March 2024 (SWE)
2024-05-09: S2Medical AB (publ) publishes the annual report for 2023 (SWE)
2024-05-06: Notice to the annual general meeting of S2Medical AB (publ) (SWE)
- Links to documents for the Annual General Meeting
2024-05-03: The board of S2Medical AB (publ) has decided that the company's annual report must also constitute a control balance sheet, which consequently postpones the company's annual report (SWE)

April
2024-04-23: S2Medical AB (publ)'s reconstruction ends successfully (SWE)
2024-04-17: S2Medical AB (publ) announces preliminary outcome of debt settlement and that the extension of the restructuring period has gained legal force (SWE)
2024-04-16: The reconstruction plan has gained legal force (SWE)

March
2024-03-26: S2Medical AB (publ) receives approval for extension of reconstruction period until April 22, 2024 (SWE)
2024-03-22: S2Medical AB (publ) secures future with approved reconstruction plan – A new era begins (SWE)
2024-03-22: S2Medical AB (publ) wins positions in procurement for wound healing products in Region Stockholm (SWE)

February
2024-02-20: S2Medical AB (publ) Year-end report 2023 (SWE)
2024-02-19: S2Medical AB (publ) informs about plan negotiations at the Linköping District Court and positive prospects for the reconstruction plan (SWE)
2024-02-19: S2Medical AB (publ) signs exclusive distribution agreement with distribution company Mad Workers LLC for the Georgian market (SWE) 
2024-02-13: S2Medical AB (publ) signs exclusive distribution agreement with Option One Enterprise for the Philippine market (SWE)
2024-02-09: S2Medical AB (publ) announces conversion options for debt conversion intended to be offered in the company's restructuring plan (SWE)
2024-02-07: S2Medical AB (publ) enters into an agreement with ABENA, which enables a positive conclusion of the reconstruction process (SWE)

January
2024-01-27: S2Medical AB (publ) Updates on ongoing contract negotiations with ABENA (SWE)
2024-01-23: S2Medical AB (publ) receives market approval for the Epiprotect series in Malaysia (SWE)
2024-01-17: S2Medical and ABENA need more days for further negotiations (SWE)
2024-01-10: New expected end date for the negotiations with ABENA (SWE)
2024-01-02: Positive final outcome in NUPCO procurement (SWE)
2024-01-02: S2Medical AB (publ) is granted an extension of corporate restructuring (SWE)

2023
2023-12-21: S2Medical AB (publ) will submit an application for an extension of the Company's restructuring in order to complete a restructuring plan and a business agreement with Abena (SWE)
2023-12-04: S2Medical AB (publ)Wins Significant Procurement in Saudi Arabia for Epiprotect (SWE)
2023-11-17: Interim report July - September 2023 (SWE)
2023-11-06: S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market
2023-08-25: Interim report April - June 2023
2023-08-23: S2Medical decides on a directed share issue of units to guarantors in connection with the completed rights issue.
2023-07-05: S2Medical AB (publ) announces final outcome in the company’s rights issue
2023-07-04: S2Medical AB Secures New Loan Agreement and Aims to be Debt-Free by July 2024
2023-07-03: S2Medical (publ) announces preliminary outcome in the company’s rights issue
Prospectus - Invitation to subscribe for units in S2Medical AB (publ) (SWE)
2023-06-16: S2Medical AB (publ) publishes a prospectus regarding the rights issue
2023-06-14: S2Medical wins positions in procurement for wound healing items in Region Kalmar County (SWE)
2023-06-08: S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia
2023-06-08: Announcement from the Annual General Meeting 2023 (SWE)
2023-05-31: Interim report January - March 2023
2023-05-17: S2Medical AB (publ) signs a distribution agreement for the Iranian market
2023-05-16: S2Medical wins procurement for wound healing items in the Västra Götaland region
2023-05-10: S2Medical AB (publ) publishes the annual report for 2022 (SWE)
2023-05-10: Postponing of publication of the quarterly report for the period January to March 2023
2023-05-09: Notice to the annual general meeting of S2Medical AB (publ) (SWE)
Link to rights issue documents
2023-05-09: S2Medical AB (publ) announces a new date for the annual general meeting and that a decision on approval of the board's decision on the rights issue will be taken in connection with it (SWE)
2023-05-05: The board of S2Medical AB (publ) decides on a partially guaranteed preferential issue of units of approximately SEK 26 million (SWE)
2023-04-24: Postponement of publication of annual report
2023-04-21: S2Medical wins procurement for wound healing items in the United Arab Emirates worth approximately SEK 3.4 million
2023-03-28: S2Medical implements a strategic change to reach profitability faster
2023-03-03: S2Medical wins procurement for wound healing equipment in Region Halland
2023-02-22: S2Medical AB (publ): Year-end report 2022
2023-02-16: Postponing of publication of the year-end report
2023-01-02: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

2022
2022-12-02: Epiprotect reduces the cost for treatment of hard to heal leg ulcers with 83%
2022-11-11: Interim report July - September 2022 (SWE)
2022-11-07: Postponing of publication of the quarterly report for the period July - September
2022-10-25: Outcome of exercise of warrants of series TO1 in S2Medical AB (publ)
2022-10-19: Application form for exercise of warrants (TO1 B) (SWE)
2022-10-18: The last day for trading in the warrants of series TO 1 in S2Medical AB (publ) is today, October 18, 2022
2022-10-14: EPO announces its intention to approve patenting of AMP technology
2022-10-14: Supply agreement signed with Region Östergötland for wound healing products
2022-10-03: Subscription price fixed for warrants of series TO1, subscription period begins on October 6, 2022
2022-09-28: Positive outcome from evaluation of Epiprotect in Saudi Arabia
2022-09-23: S2Medical AB (publ) has signed an exclusive distribution agreement for Portugal
2022-09-20: Ministry of Health and Prevention in UAE procures Epiprotect for a value of approximately 7 MSEK
2022-09-16: Epiprotect classified as skin substitute will increase reimbursement rates and create market advantages
2022-09-09: Instagraft-patent approved in Israel
2022-08-24: European Patent Office approves instagraft patent
2022-08-20: Interim report April -June 2022
2022-07-26: S2Medical AB (publ) signs exclusive distribution agreement for the Qatari market
2022-06-15: S2Medical wins procurement in Femklövern worth up to 6 MSEK
2022-06-15: Controlling body announces approval for increased shelf life of Epiprotect
2022-06-08: S2Medical AB (publ) announces change of CFO
2022-06-01: Announcement from the Annual General Meeting 2022 (SWE)
2022-05-24: S2Medical AB (publ) announces conversion of BTU, first day of trading in warrants of series TO 1 and a correction regarding the number of shares
2022-05-17: Interim report January - March 2022
2022-05-10: S2Medical AB (publ) announces outcome of rights issue
2022-05-03: Link to postal voting form
2022-05-03: Notice of Annual General Meeting of S2Medical AB (publ) (SWE)
2022-04-28: S2Medical AB (publ) wins procurement in Region Jönköping
2022-04-26: S2Medical AB (publ) publishes annual report for 2021
2022-04-26: S2Medical AB (publ) - Annual report for 2021
2022-04-14: S2Medical AB (publ) publishes EU-growth prospectus in connection with the forthcoming rights issue of units
2022-04-14: Bulletin from extraordinary general meeting of S2Medical AB (publ)
2022-04-13: Epiprotect receives Oracle code within Mediclinic in the United Arab Emirates
2022-03-15: Notice to attend the general meeting of S2Medical AB (publ)
2022-03-15: S2Medical AB (publ) resolves on a rights issue of units of approximately 30,1 MSEK guaranteed up to 70 percent
2022-03-04: S2Medical AB (publ) has received a record order of the wound healing dressing Epiprotect from Sweden
2022-03-01: ARIPO declares patent protection for the instagraft technology
2022-02-24: Arabian Trade House has placed its first order of Epiprotect
2022-02-18: S2Medical AB (publ): Year-end report 2021
2022-02-16: Epiprotect registered as class IIb in Saudi Arabia

ALL FILES BELOW ARE IN SWEDISH

2021
2021-12-30: Minutes taken at the Extraordinary General Meeting of S2Medical AB
2021-12-30: Announcement from the Extraordinary General Meeting 2021
2021-12-17: Instagraft is granted a patent in Saudi Arabia
2021-12-15: Link to postal voting form
2021-12-13: Notice of Extraordinary General Meeting of S2Medicial AB (publ)
2021-12-08: S2Medical AB (publ) has received a request to an Extraordinary General Meeting to conduct the election of the Board
2021-12-06: S2Medical AB (publ) receives certification for ISO13485
2021-12-03: S2Medical AB (publ) has won a procurement of Epiprotect in five Swedish regions valued at 13 MSEK
2021-11-25: S2Medical AB (publ) has signed an extension of the existing framework agreement with Region Halland until 2023
2021-11-23: Interim report July - September 2021 S2Medical AB (publ)
2021-10-29: S2Medical AB (publ) has through its wholly owned subsidiary Curenc AB carried out a patent application for a new group of peptides with the potential to revolutionize the treatment of multi-resistant bacteria
2021-10-29: S2Medical AB (2021-10-29: S2Medical AB (publ) receives loan financing for a total of SEK 10 million): receives loan financing for a total of SEK 10 million
2021-10-28: S2Medical AB (publ) has completed certification audit for ISO13485: 2016
2021-10-07: S2Medical AB (publ) receives full market approval in the United Arab Emirates
2021-10-05: S2Medical AB (publ) signs exclusive distribution agreement for the Saudi Arabian market
2021-08-23: Interim report April - June 2021 S2Medical AB (publ)
2021-08-02: S2Medical AB (publ) signs distribution agreements in the South Korean market
2021-07-26: Positive results for Epiprotect in a large independent study
2021-07-09: S2Medical AB (publ) completes the acquisition of Curenc AB through a directed set-off issue
2021-07-08: S2Medical announces change of Certified Adviser to Vator Securities
2021-07-08: S2Medical AB (publ) signs exclusive distribution agreement with Euroresearch s.r.l
2021-07-05: New record order from the United Arab Emirates
2021-07-01: Positive results for Epiprotect in new independent study
2021-06-23: Instagraft is granted patent protection in Japan and China
2021-06-01: Bulletin from the 2021 Annual General Meeting from the 2021 Annual General Meeting
2021-06-01: S2Medical AB (publ) products ivaQ and Epiprotect approved for CE marking
2021-05-20: Interim report January - March 2021 S2Medical AB (publ)
2021-05-03: Notice of Annual General Meeting of S2Medical AB (publ)
2021-04-26: S2Medical AB (publ) publishes annual report for 2020
2021-03-23: S2Medical AB (publ) has received the largest order of the Epiprotect wound healing bandage in the Company's history
2021-03-16: The National Medical Products Administration grants Epiprotect market approval in China
2021-03-05: S2Medical AB (publ): Year-end report 2020
2021-02-19: S2Medical AB (publ) signs exclusive distribution agreement for the South African market
2021-02-17: S2Medical AB (publ) secures delivery of protective equipment to healthcare for approximately SEK 800,000
2021-02-12: S2Medical AB (publ) wins procurement in the Stockholm Region by signing a distribution agreement with Ynolens AS
2021-02-04: S2Medical AB (publ) rights issue registered - conversion of BTA into shares

2020

2020-12-29: S2Medical AB (publ) wins procurement in the United Arab Emirates
2020-12-18: S2Medical AB (publ) expands in Europe and employs a regional sales manager
2020-12-11: S2Medical AB (publ) will be added approximately 26.2 MSEK in cash, partly through an oversubscribed rights issue and partly through a decided over-allotment
2020-12-10: S2Medical AB (publ) secures delivery of protective equipment for approx. SEK 600,000
2020-12-03: S2Medical AB (publ) has won a procurement of Epiprotect in Sweden to an estimated value of approximately 4,500,000 SEK
2020-11-30: S2Medical AB (publ) wins procurement in Kuwait
2020-11-27: S2Medical AB (publ) secures delivery of protective equipment to healthcare for approximately 2,400,000 SEK
2020-11-23: S2Medical AB (publ) secures supply agreement for sale of Epiprotect to Ministry of Health and Prevention in the United Arab Emirates
2020-11-23: Interim report July - September 2020 S2Medical AB (publ)
2020-11-20: The start of trading in S2Medical AB's subscription rights (TR B) and paid subscribed share (BTA B) starts on Tuesday 24 November
2020-11-20: S2Medical AB (publ) publishes an information memorandum in connection with the Rights Issue and the subscription period begins
2020-11-18: S2Medical AB (publ) secures delivery of protective equipment to healthcare for approximately 1,600,000 SEK
2020-11-11: Correction from today, 11 November 2020 "S2Medical AB (publ) carries out an offensive rights issue of shares of approximately 21.2 MSEK"
2020-11-11: S2Medical AB (publ) carries out an offensive rights issue of shares of approximately 21.2 MSEK
2020-11-02: S2Medical AB (publ) wins major procurement in the United Arab Emirates
2020-10-22: Positive results for eiratex in biocompatibility study
2020-10-12: S2Medical AB (publ) acquires technology for combating infections
2020-10-07: Patent protection for unique manufacturing technology in China
2020-10-05: New study shows that Epiprotect heals burns in half the time compared to standard treatment
2020-10-02: The world-unique transplant equipment Instagraft® is granted a patent in the USA
2020-09-09: S2Medical AB (publ) signs distribution agreements for the Bahraini market
2020-09-08: Test results confirm the potential of eiratex as an implant
2020-08-28: Patent protection for unique manufacturing technology in the USA
2020-08-24: EAPO issues patent protection for instagraft technology in Eurasia
2020-08-21: Interim report April - June 2020 S2Medical AB (publ)
2020-08-18: S2Medical AB (publ) secures delivery of healthcare materials for approximately 600,000 SEK
2020-08-17: S2Medical Ab (publ) has recruited a new Chief Financial Officer
2020-08-12: Positive results for Epiprotect in new independent prospective study
2020-07-24: Claims from a former distributor in the United Arab Emirates are considered unfounded and all claims for compensation are rejected in their entirety
2020-06-11: Bulletin from the Annual General Meeting
2020-06-03: S2Medical AB (publ) secures delivery of healthcare materials for approximately 1.7 MSEK
2020-05-22: Interim report January - March 2020 S2Medical AB (publ)
2020-05-15: S2Medical AB (publ) secures delivery of healthcare materials for approximately 4 MSEK
2020-05-14: Update of order status and information policy regarding ongoing COVID-19 pandemic
2020-05-13: Notice of Annual General Meeting of S2Medical AB (publ)
- Power of attorney form for S2Medical AB (publ) Annual meeting 11 June 2020
2020-04-24: S2Medical AB (publ) publishes annual report for 2019
2020-04-23: Correction: Incorrect reference to MAR in previous press release "S2Medical AB (publ) announces new date for AGM 2020" 
2020-04-23: S2Medical AB (publ) announces a new date for the 2020 Annual General Meeting
2020-03-20: S2Medical AB (publ) receives orders of approximately 1,100,000 SEK
2020-03-19: S2Medical AB (publ) receives two orders for a total of approximately 3,000,000 SEK
2020-03-17: S2Medical AB (publ) receives a new record order of approximately SEK 7,600,000
2020-03-13: S2Medical AB (publ) receives a new order of approximately 3,700,000 SEK
2020-03-13: S2Medical AB (publ) receives a new record order of approximately 4,000,000 SEK
2020-03-13: S2Medical AB (publ) receives a record order of approximately 2,500,000 SEK
2020-03-12: S2Medical AB (publ) receives orders of approximately 700,000 SEK
2020-03-11: S2Medical AB (publ) receives a large order worth approximately 900,000 SEK
2020-03-06: S2Medical AB (publ): Year-end report 2019
2020-03-02: Italian authorities grant patent protection for ivaQ technology in Italy
2020-02-26: OAPI announces patent protection for instagraft technology in Africa

2019

2019-12-18: S2Medical AB (publ) signs distribution agreement for the drug NexoBrid
2019-12-11: S2Medical AB (publ) receives compensation claims from previous distributors
2019-11-22: Interim report July-September 2019 S2Medical AB (publ)
2019-11-19: S2Medical AB (publ) signs distribution agreements for the German market
2019-11-16: PRV announces trademark protection for ivaQ
2019-10-28: S2Medical AB (publ) has recruited a CFO
2019-09-26: S2Medical AB (publ) has received the largest order from Epiprotect in the Company's history
2019-09-26: Complementation of previously issued press release S2Medical AB (publ) strengthens sales by changing distributor in the United Arab Emirates
2019-09-26: S2Medical AB (publ) strengthens sales by changing distributor in the United Arab Emirates
2019-09-25: S2Medical AB (publ) opens sales office in the Middle East
2019-08-30: PRV issues patents for instagraft technology
2019-08-30: S2Medical AB (publ) with partners has been granted approximately 30 million SEK in research grants to develop a new generation of wound healing materials
2019-08-26: S2Medical AB (publ) receives important order from reference hospital in Saudi Arabia
2019-08-23: Interim report April-June 2019 S2Medical AB (publ)
2019-07-02: Great progress for Epiprotect in the United Arab Emirates
2019-05-30: Decisions from the Medical Products Agency affect the Epiprotect series in Sweden
2019-05-24: CEO and Chief Medical Officer buy shares in S2Medical AB (publ)
2019-05-24: The patent behind the world-unique transplant equipment Instagraft® will be approved in South Africa
2019-05-23: Correction and supplementation of previously issued press release S2Medical AB (publ): Interim report for the first quarter of 2019
2019-05-23: S2Medical AB (publ) publishes interim report for the first quarter of 2019
2019-05-17: Bulletin from the Annual General Meeting
2019-05-14: Results from the pilot study are published in the journal Burns Open
2019-05-07: S2Medical AB (publ) signs distribution agreements for the Omani market
2019-04-25: S2Medical AB (publ) publishes annual report for 2018
2019-04-17: Notice of Annual General Meeting of S2Medical AB (publ)
 - Power of attorney form for S2Medical AB (publ) Annual meeting 16 may 2019
2019-04-11: S2Medical AB (publ) signs distribution agreements for the Bahraini market
2019-04-09: S2Medical AB (publ) brings forward the publication of the annual report
2019-03-06: S2Medical AB (pub): Year-end report 2018
2019-02-19: S2Medical signs important distribution agreement for the French market
2019-02-02: PRV will grant the patent application for Instagraft technology
2019-01-29: SivlerSkog Group AB has sold a small part of its holding
2019-01-27: S2Medical AB (publ) recruits one of Sweden's leading plastic surgeons
2019-01-22: S2Clinic's first patient is healed, which stops more than two years of suffering
2019-01-17: Breakthrough in one of S2Medical's development projects: In vivo tests of antimicrobial peptide show strong effect against multi-resistant bacteria
2019-01-16: S2Medical AB (publ) begins clinical study with the world-unique transplant equipment Instagraft® for the purpose of combating chronic wounds